Clinical Outcomes With A New Monofocal Intraocular Lens
Published 2023 - 41st Congress of the ESCRS
Reference: PP10.17 | Type: Free paper | DOI: 10.82333/mxr6-as52
Authors: Stephen Hannan* 1 , David Teenan 1 , Jan Venter 1 , Sandro Di Simplicio 1 , Igo Occhipinti 1 , Huba Kiss 1 , Manu Mathew 1 , Eric Donnenfeld 2 , Steven Dell 3
1Optical Express,Glasgow,United Kingdom, 2Ophthalmology,New York University Medical Centre,New York,United States, 3Ophthalmology, Cataract & Refractive Surgery,Dell Laser Consultants,Austin,United States
Purpose
To report on the safety and efficacy outcomes of the new TECNIS Eyhance premium Monofocal IOL indicated for patients looking for an extended benefit from a monofocal lens.
Setting
Private Refractive Surgery (Optical Express)
Methods
Real world outcomes of 1,500 patients who underwent cataract surgery or refractive lens exchange with implantation of the TECNIS Eyhance IOL are reported. The age range of patients was 36 to 92 years, with pre-op refractive range of +9.50D to -16.75D and up to -4.00D of refractive astigmatism. Post-implant clinical safety and efficacy outcomes in addition to patient reported outcomes were examined.
Results
Mean postoperative binocular distance visual acuity was +0.01 logMAR; intermediate visual acuity was +0.09 logMAR; and near visual acuity was +0.35 logMAR. The mean gain of lines for distance visual acuity was 6, lines gained of intermediate was 6 and 6 lines of near visual acuity. 45 of the 3,000 implanted eyes recorded >2 lines loss of BCDVA, 1.5%. Procedure recommendation rate was 93%. Adverse event rates with this premium IOL remain low.
Conclusions
The safety and efficacy outcomes for this new premium monofocal IOL suggest it may be a good selection for patients looking for meaningful gains in intermediate range. Longer follow-up is warranted to better understand the comparative performance of this IOL.